Stocks to buy

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true. However, the latest political paradigm shift warrants a different discussion.
Despite unfavorable market conditions for the past year, consumer spending has not slowed. Consumer spending has exploded over the pandemic, growing from $484.5 million in 2021 to $535.7 million in 2023, representing a 10.5% increase over two years. Despite positive growth trends, Nike (NYSE:NKE) faced difficulties recently. Nike’s stock price slipped 24% in the past
It’s not just big tech stocks that have experienced a pullback lately. Many other highly-followed stocks have as well, including some of blue-chip stocks. Blue-chips may be known for their consistency and perceived lower levels of risks, but many investors have in recent months become fairly cautious about many names in this category. In some
Real estate investment trusts (REITs) represent one of the best ways to get exposure to investing in real estate without having to take on the risks and capital expenditures of purchasing your own property. When buying into a REIT, investors are essentially giving their money as a loan to a capital management firm, which then
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options. The most popular tool in the niche is CRISPR-Cas9, which has been touted for its precision, speed, and
We’re still early in the second-quarter earnings cycle. So far, it has mostly been the banks and credit card companies that have reported Q2 results. Earnings from the mega-cap technology names are on deck next. However, FactSet reports that with 14% of S&P 500 companies having announced Q2 numbers, 80% have reported better-than-expected profits and